# A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

> **NCT02343536** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 59 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular

## Interventions

- **DRUG:** Oral Azacitidine
- **DRUG:** Rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02343536
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-29
- **Primary completion:** 2020-01-29
- **Final completion:** 2020-01-29
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343536, "A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02343536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*